جست‌وجوی استاد و پژوهشگر

Karan S Dixitمشاهده پروفایل

استادیار

• Neuro-Oncology
• Brain Tumors
• Glioblastoma
• +۴ مورد دیگر

Karan S Dixit, MD is an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in neuro-oncology and serving as Fellowship Director for the education program. His educational background includes: MD from Louisiana State University (2011) Internal Medicine Internship at University of Illinois at Chicago (2012) Neurology Residency and Chief Medical Resident at University of Illinois at Chicago (2015) Neuro-Oncology Fellowship at Northwestern University McGaw Medical Center (2016) He maintains board certification in Neurology (American Board of Psychiatry and Neurology) and Neuro-Oncology (United Council for Neurologic Subspecialties). Dr. Dixit's research centers on CNS lymphoma, lower-grade gliomas, and glioblastoma, with emphasis on novel therapies for treatment resistance. He investigates biomarkers for disease monitoring and explores neurocognitive decline mechanisms related to neural connectivity changes during CNS cancer treatment. His work bridges clinical neurology with translational oncology through molecular diagnostics and therapeutic innovation. His 2025 publications reveal three critical research trajectories: molecular characterization of glioma mutations (TERT/IDH), liquid biopsy applications for CNS lymphoma diagnosis, and repurposing antiseizure drugs with antineoplastic potential. These studies collectively advance precision medicine approaches for treatment-resistant CNS malignancies. Professional recognition includes: John A Kessler Teaching Award (2022, 2019) NeuroNEXT Fellow (2020) Society of Neuro-Oncology Clinical Trials Course (2019) University of Illinois Teaching Excellence Awards (2014-2015) As Fellowship Director, Dr. Dixit mentors neuro-oncology trainees while leading three active clinical trials: Vorasidenib/Pembrolizumab for IDH-mutant glioma (NCT05484622), NX-5948 BTK degrader for CNS lymphoma (NCT05131022), and emavusertib for relapsed PCNSL (NCT03328078). His industry collaborations include Bluprint Oncology Concepts and Servier Pharmaceuticals for therapeutic development. He maintains active membership in the Feinberg Academy of Medical Educators, American Neurological Association, American Academy of Neurology (Neuro-Oncology Section), American Society of Clinical Oncology, and Society of Neuro-Oncology, collaborating through Northwestern Medicine's Robert H. Lurie Comprehensive Cancer Center and Clinical and Translational Sciences Institute.

• Cancer Biology
• Gene Regulation
• Breast Cancer
• +۶ مورد دیگر

Dr. Thomas A. Hughes is an Associate Professor of Cancer Biology at the University of Leeds and Professor of Biosciences at York St John University. As a Group Leader at the Leeds Institute of Medical Research, he focuses on gene regulation, tumour microenvironment, and nanomedicine approaches to improve cancer outcomes. Specializes in breast cancer, colorectal cancer, and rare diseases Develops therapeutic strategies using microRNAs and biomarkers Collaborates with clinicians, engineers, and chemists for translational research His research integrates molecular pathology with clinical data through partnerships with Leeds NHS Trusts, aiming to identify novel biomarkers and targets for therapy. Recent work emphasizes cholesterol metabolism, oxysterol signaling, and nanomedicine-based drug delivery systems. Key contributions include: Over 80 peer-reviewed publications in cancer biology and molecular therapeutics Leadership in MSc programs in Molecular Medicine and Cancer Biology and Therapy Extensive experience in grant review, editorial work, and doctoral supervision Scientific awards include Fellowship of the Higher Education Academy. His lab has mentored 26 doctoral students and numerous alumni in academia, clinical practice, and industry.

• Immuno-oncology
• Cancer Immunology
• Tumor Microenvironment
• +۳ مورد دیگر

Kurt Schalper, MD, PhD is an Associate Professor of Pathology at Yale School of Medicine and Director of the Translational Immuno-Oncology Laboratory (T.I.L.) at Yale Cancer Center. His primary appointment is in the Department of Pathology with secondary appointments in Medical Oncology and Hematology. Dr. Schalper maintains affiliations with multiple cancer research entities including the Cancer Immunology Program, Yale Center for Immuno-Oncology, and the Yale Combined Program in the Biological and Biomedical Sciences (BBS). Dr. Schalper trained as a cell biologist and surgical pathologist, completing his MD at San Sebastian University (2003) and PhD at Universidad Catolica de Chile (2008). His postdoctoral work at Yale focused on developing quantitative strategies to measure immunotherapy-related biomarkers in immune cells and cancer tissues. His research centers on understanding the immunobiology of human solid tumors, particularly lung cancer, with emphasis on immune evasion mechanisms, tumor microenvironment dynamics, and biomarker development for immunotherapy response prediction. Current scientific interests include tumor immune heterogeneity, editing, and the role of specific tumor antigens and immune evasion pathways in lung malignancies. Analysis of Dr. Schalper's recent publications reveals a strong focus on immuno-oncology, particularly in lung cancer. His work spans biomarker development, mechanisms of immunotherapy resistance, tumor microenvironment characterization, and clinical translation of immunotherapeutic approaches. Notable themes include the investigation of KEAP1/STK11-related resistance, IL-4 mediated immune evasion, and strategies to overcome immunotherapy resistance through combination approaches. Dr. Schalper collaborates extensively with Yale researchers, particularly with Dr. David Rimm (57 common publications), Dr. Roy S. Herbst (35 common publications), Dr. Scott Gettinger (14 common publications), and Dr. Sarah Goldberg (12 common publications). His work appears in high-impact journals including Nature, Journal of Clinical Investigation, and Nature Reviews Clinical Oncology. As Director of the Translational Immuno-Oncology Laboratory, Dr. Schalper leads efforts to produce and support high-quality translational research in immuno-oncology through standardized biomarker analyses and integration with Yale resources. His laboratory focuses on developing quantitative methods for immunotherapy biomarker assessment and understanding mechanisms of response and resistance to cancer immunotherapies.

• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• +۴ مورد دیگر

Nikolai Podoltsev, MD, PhD, is an Associate Professor of Medicine (Hematology) at Yale University School of Medicine. He serves as the Associate Director of the Hematology/Oncology Fellowship Program and Clinical Director of Malignant Hematology within the Department of Internal Medicine. Dr. Podoltsev is also the director of the Hematology/Leukemia Tumor Board and represents Yale Cancer Center on National Comprehensive Cancer Network (NCCN) clinical practice guidelines panels, including the Myeloproliferative Neoplasms Panel. Dr. Podoltsev's research focuses on the management of patients with acute leukemias (including acute myeloid leukemias and acute lymphoblastic leukemia), myeloid neoplasms (such as myelodysplastic syndromes and myeloproliferative neoplasms), and bone marrow failure syndromes. His work spans clinical research, epidemiology, and patterns of care for patients with hematological malignancies. As a principal investigator, he leads multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies. Analysis of Dr. Podoltsev's recent publications (2024-2025) reveals a strong focus on therapeutic advancements in myeloid malignancies, particularly acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis. His research spans drug development (including novel agents like imetelstat and luspatercept), combination therapies, treatment sequencing, and cost-effectiveness analyses. There is a clear emphasis on translating molecular understanding into clinical applications, with significant work on targeted therapies for specific genetic mutations. Yale Cancer Center Award for Clinical Excellence (2022) The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology (2021, 2017, 2011) As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital Duffy Firm Chief for Education, Dr. Podoltsev plays a pivotal role in hematology education for fellows, residents, and medical students. He is actively involved in multiple clinical trials through the Leukemia Clinical Research Team and the Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, which enables him to study epidemiology and patterns of care for hematological malignancies. Dr. Podoltsev is part of the Leukemia Disease Aligned Research Team (DART) at Yale Cancer Center, where he contributes to advancing treatment options for patients with blood cancers. His clinical expertise spans the full spectrum of malignant hematology with a particular focus on older adult patients.

Franz Lennard Ricklefsمشاهده پروفایل

استاد

• Neurosurgery
• Neuro-oncology
• Molecular Neurobiology
• +۵ مورد دیگر

Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.

• Spine Surgery
• Neurosurgery
• Orthopedics
• +۴ مورد دیگر

Mihir Gupta, MD, is an Assistant Professor of Neurosurgery at Yale School of Medicine. As a fellowship-trained spine surgeon with dual expertise in neurosurgery and orthopedics, he performs both traditional and minimally invasive procedures for complex spinal disorders including degenerative conditions, deformities, tumors, infections, and trauma-related issues. Dr. Gupta also specializes in revision spine surgeries for patients with persistent or new problems following previous operations. Dr. Gupta's educational background includes a BA from Harvard College, an MD from Stanford University School of Medicine, neurosurgical residency at the University of California San Diego, postdoctoral studies at Harvard Medical School, and an orthopedic spine surgery fellowship at Johns Hopkins University. His clinical philosophy emphasizes understanding each patient's unique story through thorough evaluation and physical examination before developing personalized treatment plans. His research interests focus on understanding how genetics contribute to different spinal disorders and how care can be personalized. Dr. Gupta's publications demonstrate expertise across multiple domains including brain tumor diagnostics (particularly CNS lymphoma and glioblastoma), spine surgery outcomes, gender diversity in academic medicine, and neuroimmunology. His work often bridges clinical practice with molecular diagnostics, emphasizing rapid testing methods that accelerate treatment decisions for brain tumor patients. Dr. Gupta collaborates extensively with multidisciplinary teams including physical therapists, pain management specialists, anesthesiologists, and interventional radiologists to develop comprehensive treatment approaches. He emphasizes that surgery is often the last resort, prioritizing nonsurgical options when appropriate. His clinical work at Yale Medicine focuses on highly personalized spine procedures using advanced robotics, navigation, and minimally invasive techniques to tailor solutions for individual patients.

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +۳ مورد دیگر

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

Li Minمشاهده پروفایل

دانشیار

• Archaeology
• Chinese Prehistoric and Bronze Age Studies
• Social Memory and State Formation
• +۳ مورد دیگر

Li Min is an Associate Professor at the University of California, Los Angeles (UCLA), affiliated with the Department of Anthropology. His research focuses on Chinese prehistoric and Bronze Age archaeology, emphasizing state formation, social memory, and climatic responses. He also studies maritime archaeology of the Asiatic Trade in the Early Modern Era, using ceramic analysis to trace global trade impacts. Li teaches graduate seminars in archaeology theories and undergraduate courses on Chinese civilizations, collaborating across Anthropology, Asian Languages and Cultures, and the Interdepartmental Program of Archaeology. He co-directs the Wen-Si River Basin archaeological project with Chinese institutions. His 2018 book, Social Memory and State Formation in Early China , is a key contribution to the field. His education includes a Ph.D. from the University of Michigan (2008). Research interests further encompass landscape archaeology, integrating ceramics analysis with remote sensing and historical records. Subfield expertise includes social archaeology, material culture studies, and historical anthropology. Recent publications (2023–2025) concentrate on neuro-oncology imaging innovations, including MRI techniques for glioma characterization, adaptive clinical trials (e.g., GBM AGILE), and biomarker development. These studies highlight advanced applications of AI in medical imaging and molecular targeting therapies for brain tumors. Despite no listed awards, his work on imaging biomarkers and tumor response assessment has advanced clinical neuro-oncology standards. He advises on interdisciplinary collaborations, such as the Wen-Si project, and participates in global clinical trials for glioblastoma therapies.

Kathryn E. Dickersonمشاهده پروفایل

استادیار

• Pediatric Hematology
• Myeloid Malignancies
• Epigenetic Regulation
• +۴ مورد دیگر

Kathryn E. Dickerson, M.D., M.S.C.S., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center, specializing in the Division of Hematology and Oncology. She holds dual appointments as a 2015 Translational Research Scholar in the UTSW Center for Translational Medicine and as an NIH KL2 scholar. Her clinical focus is pediatric hematology, emphasizing bone marrow failure disorders, cancer predisposition syndromes, and thalassemia/dyserythropoietic anemias. Her research investigates epigenetic regulation of myeloid malignancies, clonal hematopoiesis in childhood cancer survivors, and molecular mechanisms underlying acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD). Education: Bachelor's in Biochemistry (Indiana University), minor in Spanish Medical degree (Indiana University School of Medicine) Masters of Science in Clinical Sciences (UT Southwestern Center for Translational Medicine) Training: Pediatric residency with research pathway (Ohio State University/Nationwide Children’s Hospital) Pediatric hematology-oncology fellowship (UT Southwestern) Dr. Dickerson’s research bridges basic science and clinical practice, leveraging CRISPR-based epigenetic editing, genomic analysis, and translational studies to understand disease mechanisms. Key projects include interrogating enhancer dysregulation in leukemia, studying metabolic reprogramming in cancers, and evaluating clonal hematopoiesis in survivors of childhood cancers. Her work has advanced understanding of EZH2’s role in AML and identified therapeutic vulnerabilities in myeloid malignancies. Awards: 2015 Translational Research Scholar (UTSW Center for Translational Medicine) NIH KL2 Career Development Award Grants/Initiatives: NIH-funded investigator-initiated study on clonal hematopoiesis Industry/consortia-sponsored trials for bone marrow failure and rare blood disorders She collaborates with the Children’s Research Institute and North American Pediatric Aplastic Anemia Consortium, contributing to clinical trials and translational initiatives. Her lab focuses on developing biomarkers for disease severity (e.g., immature platelet fraction in pediatric COVID-19) and therapeutic strategies targeting epigenetic dependencies in leukemia.

• Medical Image Computing
• Tumor Growth Modeling
• Computational Physiology
• +۳ مورد دیگر

Bjoern Menze is a Professor and Rudolf Mößbauer Tenure Track Chair at the Technical University of Munich (TUM), leading the Image-based Biomedical Modeling Group within the Munich School of Bioengineering. His research focuses on medical image computing, tumor growth modeling, and computational physiology, with applications in clinical neuroimaging and personalized radiotherapy design. He holds a Ph.D. in Computer Science from Heidelberg University and has held positions at ETH Zurich, INRIA Sophia Antipolis, MIT, and Harvard Medical School. His academic journey includes a postdoc at MIT’s CSAIL and Harvard Medical School, followed by roles at ETH Zurich and INRIA. His work bridges biomedical imaging with machine learning, emphasizing model-driven analysis of physiological processes. He has been a visiting professor at Maastricht University and contributes to initiatives like the Center for Translational Cancer Research at TUM. Key research areas include tumor growth modeling, quantitative imaging biomarkers, and integrating mathematical models with clinical data. His awards include the MICCAI Young Scientist Award (2014), Leopoldina Fellowship (2009), and DFG Research Fellowship (2008). He advises on medical AI, leads interdisciplinary projects, and publishes extensively in top journals like Nature Neuroscience and IEEE Transactions on Medical Imaging. His lab’s work spans applications such as glioblastoma radiotherapy optimization, whole-body bone lesion detection, and neural connectivity imaging. Collaborations include institutions like Harvard, MIT, and ETH Zurich. He emphasizes translating computational methods into clinical practice for personalized healthcare solutions.

Alastair Smithمشاهده پروفایل

استاد

• International Relations
• Political Science
• Political Economy
• +۳ مورد دیگر

Alastair Smith is the Bernhardt Denmark Professor of International Relations at New York University's Department of Politics, part of the College of Arts & Science. He holds a Ph.D. from the University of Rochester (1995) and a B.A. (Hons) in Chemistry from the University of Oxford (1990). His research focuses on international relations, electoral politics, and political economy, with notable works including *The Dictator's Handbook* (2011) and *The Logic of Political Survival* (2003, co-authored). His research explores authoritarian regimes, conflict dynamics, and the strategic calculus of leaders in international negotiations. Recent scholarship addresses topics such as UN Security Council influence on conflict reduction, electoral timing effects on negotiations, and the political economy of climate agreements. He has contributed to debates on punishment strategies in governance (*The Punisher's Dilemma*, 2024) and the role of regime type in coalition warfare efforts (2023). His work bridges theoretical political science with empirical analysis of global governance challenges. Smith's academic contributions span books, peer-reviewed articles, and policy analyses. He has advised on international relations topics and collaborates across disciplines, occasionally engaging in interdisciplinary studies (e.g., genetics and Alzheimer’s resilience). His contact includes the NYU Politics Department address and email provided.

Maureen Sartorمشاهده پروفایل

استاد

• Epigenetics
• Bioinformatics
• Cancer Research
• +۷ مورد دیگر

Maureen Sartor is a Professor in the Department of Computational Medicine and Bioinformatics at the University of Michigan Medical School. Her work bridges computational biology, epigenetics, and cancer research, with recent contributions to understanding environmental toxicant impacts on DNA methylation, HPV-associated head and neck cancers, and neurodegenerative disease mechanisms. Key research themes: Epigenetic regulation, bioinformatics modeling, environmental health Active clinical trial collaborations in immunotherapy rechallenge and neoadjuvant treatment strategies Leadership in cross-species toxicoepigenetic studies and microbiome-immune crosstalk in oral cancer Recent publications highlight her expertise in: Epigenetic age acceleration in ALS and its environmental correlates HPV integration mechanisms in oropharyngeal cancer Chemical oxidation techniques for piRNA discovery Sex-specific epigenetic responses to lead and phthalate exposure Her interdisciplinary approach connects computational methods with experimental validation across multiple disease models.

Sheng Liمشاهده پروفایل

دانشیار

• Cancer Epigenetics
• Aging
• Clonal Hematopoiesis
• +۳ مورد دیگر

Sheng Li is an Associate Professor of Cancer Biology at the University of Southern California's Keck School of Medicine. She co-leads the Epigenetic Regulation in Cancer Program at the Norris Comprehensive Cancer Center. Her research integrates multi-omics and computational approaches to study epigenetic heterogeneity in blood cancers, aging, and clonal hematopoiesis. Her lab focuses on single-cell spatial multi-omics, 3D epigenomics, and long-read sequencing to map epigenetic drivers of leukemogenesis. Awards include the Leukemia & Lymphoma Society Scholar Award and AACR NextGen Star recognition. She mentors PhD students and postdocs, with her team publishing extensively in high-impact journals. Her publications demonstrate a strong emphasis on computational epigenetics, cancer systems biology, and geroscience. Recent work includes developing tools for spatial transcriptomics interpretation and modeling IDH-mutant AML gene networks.

Ingo Mellinghoffمشاهده پروفایل

استاد

• Neuro-Oncology
• Brain Tumor Research
• Molecular Pathways in Cancer
• +۵ مورد دیگر

Ingo K. Mellinghoff is a physician-scientist and Professor at Memorial Sloan Kettering Cancer Center (MSKCC), serving as Chair of the Department of Neurology. He leads the Human Oncology & Pathogenesis Program (HOPP) laboratory, focusing on molecular mechanisms of brain tumor growth, particularly gliomas and primary CNS lymphomas. His work bridges experimental models and clinical trials, emphasizing targeted therapies and liquid biopsy applications. Affiliations: Brain Tumor Center, Gerstner Sloan Kettering Graduate School Research interests include IDH mutations, tumor metabolism, microenvironment interactions, and biomarker-driven trials. Notable achievements include advancing vorasidenib (a mutant IDH inhibitor) to phase 3 trials and developing cerebrospinal fluid-based liquid biopsy techniques for glioma monitoring. Recent articles highlight clinical trial results for IDH inhibitors and translational studies on tumor biology. Awards include the Neuro-Oncology Scientific Award (2023) and membership in prestigious medical societies.

Andreas Stadlbauerمشاهده پروفایل

استاد مدعو

• Biomedical Imaging
• Medical Physics
• Artificial Intelligence in Medicine
• +۷ مورد دیگر

Prof. Dr. Andreas Stadlbauer is a medical physicist affiliated with the Clinical Institute for Diagnostic and Interventional Radiology at St. Pölten University Hospital and the Department of Neurosurgery at Friedrich-Alexander University Erlangen-Nuremberg. He holds an adjunct professorship at the University of Erlangen-Nuremberg and contributes to both clinical and academic research in biomedical imaging and AI applications in oncology. University: Friedrich-Alexander University Erlangen-Nuremberg Hospital Affiliation: St. Pölten University Hospital Department: Department of Neurosurgery Academic Rank: Adjunct Professor His research focuses on advanced MRI techniques, particularly physio-metabolic imaging of brain tumors, oxygen metabolism, and the integration of artificial intelligence in clinical diagnostics. He has led research on glioma classification, tumor microenvironment characterization, and deep learning models for radiomic analysis. The recent publications highlight a strong trend toward AI-driven diagnostic tools in neuro-oncology, particularly in differentiating glioblastomas from metastases and predicting genetic mutations using machine learning. His work emphasizes the clinical translation of complex imaging data into actionable insights. Artificial Intelligence in Oncology Medical Imaging and Radiomics Brain Tumor Metabolism Deep Learning for MRI Analysis Oxygen Metabolism Imaging Clinical Decision Support Systems Prof. Stadlbauer has been involved in seed-funded research projects developing deep learning algorithms for clinical integration. He collaborates extensively with neurosurgeons, radiologists, and oncologists across institutions, contributing to multidisciplinary tumor boards and translational research initiatives. He completed his doctorate in medical physics in 2004, habilitation in 2008, and an MBA in Health Management in 2010. His academic journey reflects a blend of technical expertise and leadership in healthcare innovation.